RVTY – Revvity Inc

RVTY — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

7.73

Margin Of Safety %

Put/Call OI Ratio

10.05

EPS Next Q Diff

0.43

EPS Last/This Y

3.34

EPS This/Next Y

0.59

Price

84.77

Target Price

117.4

Analyst Recom

2.29

Performance Q

-12.37

Upside

-45.8%

Beta

1.14

Ticker: RVTY

15 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-09	RVTY	92.1	0.30	0.11	1979
2026-03-10	RVTY	90.31	0.30	0.05	1979
2026-03-11	RVTY	89.6	0.23	0.20	2129
2026-03-12	RVTY	84.7	0.23	463.00	2135
2026-03-13	RVTY	84.76	0.23	51.89	2135
2026-03-17	RVTY	87.42	3.24	0.15	8652
2026-03-18	RVTY	84.87	3.23	53.00	8655
2026-03-19	RVTY	85.76	3.23	0.06	8668
2026-03-20	RVTY	85.95	3.18	1.44	8725
2026-03-23	RVTY	87.18	7.19	0.40	7382
2026-03-24	RVTY	87.44	7.09	0.29	7408
2026-03-25	RVTY	87.82	7.02	0.10	7419
2026-03-26	RVTY	87.1	6.95	0.14	7430
2026-03-27	RVTY	83.89	6.91	752.25	7435
2026-03-30	RVTY	84.77	10.05	0.09	10434
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

15 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-02	RVTY	95.55	0.9	293.3	5.41
2026-03-03	RVTY	95.96	0.9	310.8	5.41
2026-03-04	RVTY	98.49	0.9	323.1	5.41
2026-03-05	RVTY	96.58	0.9	298.1	5.41
2026-03-06	RVTY	91.38	0.9	279.3	5.41
2026-03-09	RVTY	92.09	0.9	313.1	5.41
2026-03-10	RVTY	90.28	0.9	298.0	5.41
2026-03-11	RVTY	89.64	0.9	304.8	5.41
2026-03-12	RVTY	84.70	0.9	279.2	5.41
2026-03-13	RVTY	85.60	0.9	313.9	5.41
2026-03-17	RVTY	87.42	0.9	314.5	5.41
2026-03-18	RVTY	84.89	0.9	293.5	5.41
2026-03-19	RVTY	85.75	0.9	157.5	5.41
2026-03-20	RVTY	85.88	0.9	154.0	5.41
2026-03-23	RVTY	87.23	0.9	159.6	5.41
2026-03-24	RVTY	87.46	0.9	154.9	5.41
2026-03-25	RVTY	87.82	0.9	155.2	5.41
2026-03-26	RVTY	87.11	0.9	150.1	5.41
2026-03-27	RVTY	83.91	0.9	138.4	5.41
2026-03-30	RVTY	84.77	0.9	157.7	5.41
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

16 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-06	RVTY	-8.29	-2.17	7.15
2026-03-09	RVTY	-8.29	-2.27	7.15
2026-03-10	RVTY	-8.29	-2.27	7.15
2026-03-11	RVTY	-8.29	-2.27	7.36
2026-03-12	RVTY	-8.29	-2.27	7.36
2026-03-13	RVTY	-8.29	-2.27	7.36
2026-03-17	RVTY	-8.29	-2.22	7.36
2026-03-18	RVTY	-8.29	-2.22	7.36
2026-03-19	RVTY	-8.29	-2.22	7.36
2026-03-20	RVTY	-8.29	-2.22	7.36
2026-03-23	RVTY	-8.28	-2.22	7.36
2026-03-24	RVTY	-8.28	-2.22	7.36
2026-03-25	RVTY	-8.29	-2.22	7.73
2026-03-26	RVTY	-8.29	-2.22	7.73
2026-03-27	RVTY	-8.29	-2.22	7.73
2026-03-30	RVTY	-8.29	-2.20	7.73
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

16 items 1 of 1

Last Quarter Act. EPS

0.87

Avg. EPS Est. Current Quarter

1.02

Avg. EPS Est. Next Quarter

1.3

Insider Transactions

-8.29

Institutional Transactions

-2.2

Beta

1.14

Average Sales Estimate Current Quarter

704

Average Sales Estimate Next Quarter

746

Fair Value

114.35

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

58.3

Max Drawdown 5-Year %

-59

Target Price

117.4

P/E

40.56

Forward P/E

14.18

PEG

1.6

P/S

3.32

P/B

1.31

P/Free Cash Flow

18.7

EPS

2.09

Average EPS Est. Cur. Y

5.41

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

8.47

Relative Volume

0.77

Return on Equity vs Sector %

-24.1

Return on Equity vs Industry %

-7.8

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

157.7

◆ RVTY Healthcare

$84.78

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

20/20

Pullback

19/25

Volume

9/15

Valuation

20/20

TP/AR

1/10

Options

1/10

RSI

35.5

Range 1M

7.8%

Sup Dist

2.7%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

7/25

Growth

13/30

Estimates

4/20

Inst/Vol

0/15

Options

3/10

EPS Yr

6.7%

EPS NY

10.7%

52W%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +46% upside

Quality

8/30

Valuation

21/30

Growth

7/25

Stability

7/10

LT Trend

4/5

Upside

+46%

Quality

MoS

35%

Revvity, Inc.

Sector: Healthcare

Industry: Diagnostics & Research

Employees: 11000

Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

RVTY

Latest News

—

Caricamento notizie per RVTY…

stock quote shares RVTY – Revvity Inc Stock Price stock today

news today RVTY – Revvity Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch RVTY – Revvity Inc yahoo finance google finance

stock history RVTY – Revvity Inc invest stock market

stock prices RVTY premarket after hours

ticker RVTY fair value insiders trading

XGN – Exagen Inc.

XGN — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

7.44

Margin Of Safety %

Put/Call OI Ratio

0.02

EPS Next Q Diff

EPS Last/This Y

0.13

EPS This/Next Y

0.49

Price

2.66

Target Price

9.5

Analyst Recom

Performance Q

-56.77

Upside

-1,315.1%

Beta

1.98

Ticker: XGN

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-02	XGN	3.54	0.07	0.08	835
2026-03-03	XGN	3.43	0.07	0.08	835
2026-03-04	XGN	3.6	0.07	0.08	835
2026-03-05	XGN	3.22	0.07	0.08	835
2026-03-06	XGN	3.29	0.07	0.00	852
2026-03-09	XGN	3.37	0.07	0.00	852
2026-03-10	XGN	3.24	0.07	0.00	853
2026-03-11	XGN	3.11	0.07	0.00	863
2026-03-12	XGN	3.16	0.07	0.00	893
2026-03-13	XGN	3.16	0.07	0.00	893
2026-03-17	XGN	3.18	0.06	10.00	913
2026-03-18	XGN	3	0.13	999.99	974
2026-03-19	XGN	2.96	0.13	999.99	974
2026-03-20	XGN	2.8	0.23	0.00	1055
2026-03-23	XGN	2.84	0.23	0.00	1055
2026-03-24	XGN	2.75	0.23	0.00	1055
2026-03-25	XGN	2.88	0.23	0.00	1055
2026-03-26	XGN	2.8	0.02	0.00	862
2026-03-27	XGN	2.68	0.02	0.00	862
2026-03-30	XGN	2.66	0.02	0.00	862
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-02	XGN	3.55	3.3	5.6	-0.84
2026-03-03	XGN	3.43	3.3	5.7	-0.84
2026-03-04	XGN	3.60	3.3	4.9	-0.84
2026-03-05	XGN	3.21	3.3	6.6	-0.84
2026-03-06	XGN	3.29	3.3	5.1	-0.84
2026-03-09	XGN	3.38	3.3	4.9	-0.84
2026-03-10	XGN	3.20	3.3	5.9	-0.84
2026-03-11	XGN	3.11	3.3	5.9	-0.84
2026-03-12	XGN	3.16	3.3	5.1	-0.84
2026-03-13	XGN	3.05	-25.0	4.1	-0.80
2026-03-17	XGN	3.19	-25.0	3.5	-0.80
2026-03-18	XGN	3.01	-25.0	14.1	-0.80
2026-03-19	XGN	2.96	-25.0	3.9	-0.80
2026-03-20	XGN	2.79	-25.0	4.5	-0.80
2026-03-23	XGN	2.86	-25.0	3.6	-0.80
2026-03-24	XGN	2.74	-25.0	4.2	-0.80
2026-03-25	XGN	2.88	-25.0	3.2	-0.80
2026-03-26	XGN	2.78	-25.0	4.2	-0.80
2026-03-27	XGN	2.68	-25.0	4.2	-0.80
2026-03-30	XGN	2.66	-25.0	3.9	-0.80
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-02	XGN	-0.79	11.08	6.12
2026-03-03	XGN	-0.79	11.08	6.12
2026-03-04	XGN	-0.98	11.08	6.12
2026-03-05	XGN	-0.73	11.08	6.12
2026-03-06	XGN	-0.73	11.08	6.12
2026-03-09	XGN	-0.73	10.99	6.12
2026-03-10	XGN	-0.73	10.99	6.12
2026-03-11	XGN	-0.73	10.99	7.40
2026-03-12	XGN	-0.73	10.99	7.40
2026-03-13	XGN	-0.69	10.99	6.97
2026-03-17	XGN	-0.69	10.62	6.97
2026-03-18	XGN	-0.69	10.62	6.97
2026-03-19	XGN	-0.69	10.62	6.97
2026-03-20	XGN	-0.69	10.62	6.97
2026-03-23	XGN	-0.69	10.63	6.97
2026-03-24	XGN	-0.69	10.63	6.97
2026-03-25	XGN	-0.69	10.63	7.44
2026-03-26	XGN	-0.69	10.63	7.44
2026-03-27	XGN	-0.69	10.63	7.44
2026-03-30	XGN	-0.69	10.63	7.44
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.2

Avg. EPS Est. Current Quarter

-0.25

Avg. EPS Est. Next Quarter

-0.2

Insider Transactions

-0.69

Institutional Transactions

10.63

Beta

1.98

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

85.6

Max Drawdown 5-Year %

-92.4

Target Price

9.5

P/E

Forward P/E

PEG

P/S

0.96

P/B

3.48

P/Free Cash Flow

EPS

-0.92

Average EPS Est. Cur. Y

-0.8

EPS Next Y. (Est.)

-0.31

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-29.97

Relative Volume

0.3

Return on Equity vs Sector %

-141.8

Return on Equity vs Industry %

-125.4

EPS 1 7Days Diff

-0.3

EPS 1 30Days Diff

-0.34

EBIT Estimation

3.9

◆ XGN Healthcare

$2.65

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

20/20

Pullback

21/25

Volume

11/15

Valuation

12/20

TP/AR

2/10

Options

5/10

RSI

31.1

Range 1M

2.5%

Sup Dist

1.5%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

8/25

Growth

21/30

Estimates

1/20

Inst/Vol

5/15

Options

7/10

EPS Yr

25.8%

EPS NY

36.9%

52W%

0.3%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +258.5% upside

Quality

5/30

Valuation

16/30

Growth

15/25

Stability

4/10

LT Trend

3/5

Upside

+258.5%

Quality

Exagen Inc.

Sector: Healthcare

Industry: Diagnostics & Research

Employees: 216

Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company's lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus platform, a cornerstone of the SLE assessment that begins by quantifying the level of CB-CAPs biomarkers (EC4d and BC4d) in the patient's blood; and AVISE APS that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE Anti-Histone, a test for autoantibodies to histone proteins; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP, a biomarker-driven RA prognostic test. Further, the company offers AVISE SLE Monitor, a blood test that employs CB-CAPs technology; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop T-Cell biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

XGN

Latest News

—

Caricamento notizie per XGN…

stock quote shares XGN – Exagen Inc. Stock Price stock today

news today XGN – Exagen Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch XGN – Exagen Inc. yahoo finance google finance

stock history XGN – Exagen Inc. invest stock market

stock prices XGN premarket after hours

ticker XGN fair value insiders trading

VCYT – Veracyte Inc.

VCYT — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

6.92

Margin Of Safety %

Put/Call OI Ratio

0.18

EPS Next Q Diff

-0.11

EPS Last/This Y

0.81

EPS This/Next Y

0.12

Price

30.44

Target Price

48.09

Analyst Recom

1.62

Performance Q

-28.36

Upside

-40.7%

Beta

1.97

Ticker: VCYT

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-02	VCYT	36.01	0.22	2.33	2964
2026-03-03	VCYT	35.09	0.22	0.00	2967
2026-03-04	VCYT	36.26	0.22	0.00	3054
2026-03-05	VCYT	34.68	0.21	0.94	3062
2026-03-06	VCYT	33.86	0.22	0.01	3074
2026-03-09	VCYT	33.36	0.18	0.00	3597
2026-03-10	VCYT	32.74	0.16	6.00	3941
2026-03-11	VCYT	32.43	0.17	4.67	3968
2026-03-12	VCYT	30.96	0.17	0.50	3977
2026-03-13	VCYT	30.93	0.17	0.50	3977
2026-03-17	VCYT	33.51	0.16	0.00	3979
2026-03-18	VCYT	33.3	0.16	0.00	3981
2026-03-19	VCYT	32.77	0.16	1.60	3985
2026-03-20	VCYT	31.87	0.16	0.33	3978
2026-03-23	VCYT	33.5	0.18	0.00	2181
2026-03-24	VCYT	32.95	0.18	4.00	2183
2026-03-25	VCYT	32.79	0.19	0.00	2193
2026-03-26	VCYT	32.76	0.18	0.00	2186
2026-03-27	VCYT	30	0.18	0.00	2208
2026-03-30	VCYT	30.45	0.18	0.06	2209
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-02	VCYT	36.01	7.5	71.5	1.66
2026-03-03	VCYT	35.06	7.5	70.2	1.66
2026-03-04	VCYT	36.27	7.5	77.3	1.66
2026-03-05	VCYT	34.66	7.5	68.0	1.66
2026-03-06	VCYT	33.86	7.5	70.5	1.66
2026-03-09	VCYT	33.33	7.5	34.2	1.65
2026-03-10	VCYT	32.76	7.5	34.0	1.65
2026-03-11	VCYT	32.44	7.5	34.8	1.65
2026-03-12	VCYT	30.92	7.5	30.3	1.65
2026-03-13	VCYT	32.15	7.5	40.8	1.65
2026-03-17	VCYT	33.50	7.5	38.1	1.65
2026-03-18	VCYT	33.32	7.5	35.5	1.65
2026-03-19	VCYT	32.78	7.5	9.3	1.65
2026-03-20	VCYT	31.84	7.5	8.2	1.65
2026-03-23	VCYT	33.52	7.5	15.6	1.65
2026-03-24	VCYT	32.95	7.5	9.1	1.65
2026-03-25	VCYT	32.78	7.5	10.3	1.65
2026-03-26	VCYT	32.78	7.5	10.8	1.65
2026-03-27	VCYT	29.99	7.5	2.9	1.65
2026-03-30	VCYT	30.44	7.5	12.2	1.65
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-02	VCYT	-9.97	-3.14	7.78
2026-03-03	VCYT	-9.97	-3.14	7.78
2026-03-04	VCYT	-10.60	-3.14	7.78
2026-03-05	VCYT	-10.60	-3.14	7.78
2026-03-06	VCYT	-13.99	-3.14	7.78
2026-03-09	VCYT	-13.66	-3.27	7.78
2026-03-10	VCYT	-13.66	-3.27	7.78
2026-03-11	VCYT	-13.66	-3.27	7.06
2026-03-12	VCYT	-13.66	-3.27	7.06
2026-03-13	VCYT	-13.66	-3.27	7.06
2026-03-17	VCYT	-13.66	-3.11	7.06
2026-03-18	VCYT	-13.66	-3.11	7.06
2026-03-19	VCYT	-13.66	-3.11	7.06
2026-03-20	VCYT	-13.66	-3.11	7.06
2026-03-23	VCYT	-13.66	-3.11	7.06
2026-03-24	VCYT	-13.56	-3.11	7.06
2026-03-25	VCYT	-13.56	-3.11	6.92
2026-03-26	VCYT	-13.56	-3.11	6.92
2026-03-27	VCYT	-13.56	-3.11	6.92
2026-03-30	VCYT	-13.56	-3.11	6.92
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

0.53

Avg. EPS Est. Current Quarter

0.33

Avg. EPS Est. Next Quarter

0.42

Insider Transactions

-13.56

Institutional Transactions

-3.11

Beta

1.97

Average Sales Estimate Current Quarter

130

Average Sales Estimate Next Quarter

144

Fair Value

32.52

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

49.1

Max Drawdown 5-Year %

-73

Target Price

48.09

P/E

37.06

Forward P/E

16.97

PEG

7.54

P/S

4.68

P/B

1.84

P/Free Cash Flow

19.1

EPS

0.82

Average EPS Est. Cur. Y

1.65

EPS Next Y. (Est.)

1.77

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

12.83

Relative Volume

1.47

Return on Equity vs Sector %

-22.4

Return on Equity vs Industry %

-6

EPS 1 7Days Diff

EPS 1 30Days Diff

0.12

EBIT Estimation

12.2

◆ VCYT Healthcare

$30.44

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

20/20

Pullback

17/25

Volume

3/15

Valuation

20/20

TP/AR

3/10

Options

6/10

RSI

35.7

Range 1M

13.8%

Sup Dist

5.6%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

7/25

Growth

14/30

Estimates

7/20

Inst/Vol

3/15

Options

10/10

EPS Yr

-6.8%

EPS NY

8.2%

52W%

28%

💎

Long-Term Value

Quality companies, undervalued

WEAK

🟡 HOLD +27.6% upside

Quality

13/30

Valuation

11/30

Growth

11/25

Stability

8/10

LT Trend

4/5

Upside

+27.6%

Quality

MoS

Veracyte, Inc.

Sector: Healthcare

Industry: Diagnostics & Research

Employees: 755

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

VCYT

Latest News

—

Caricamento notizie per VCYT…

stock quote shares VCYT – Veracyte Inc. Stock Price stock today

news today VCYT – Veracyte Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch VCYT – Veracyte Inc. yahoo finance google finance

stock history VCYT – Veracyte Inc. invest stock market

stock prices VCYT premarket after hours

ticker VCYT fair value insiders trading

CSTL – Castle Biosciences Inc.

CSTL — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

4.94

Margin Of Safety %

Put/Call OI Ratio

0.21

EPS Next Q Diff

-0.23

EPS Last/This Y

-0.34

EPS This/Next Y

0.63

Price

23.56

Target Price

48.5

Analyst Recom

1.12

Performance Q

-40.22

Upside

-226.3%

Beta

1.21

Ticker: CSTL

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-02	CSTL	27.99	0.27	0.04	1793
2026-03-03	CSTL	27.33	0.27	1.00	1806
2026-03-04	CSTL	28.2	0.27	0.00	1807
2026-03-05	CSTL	27.89	0.27	0.00	1807
2026-03-06	CSTL	27.09	0.27	1.57	1807
2026-03-09	CSTL	26.97	0.27	0.09	1807
2026-03-10	CSTL	26.58	0.26	0.00	1808
2026-03-11	CSTL	26.14	0.26	0.00	1825
2026-03-12	CSTL	25.29	0.26	0.00	1826
2026-03-13	CSTL	25.32	0.26	0.00	1826
2026-03-17	CSTL	25.89	0.26	0.00	1829
2026-03-18	CSTL	25.62	0.25	0.10	1828
2026-03-19	CSTL	25.69	0.25	0.00	1847
2026-03-20	CSTL	25.05	0.20	0.00	1783
2026-03-23	CSTL	25.71	0.25	999.99	1437
2026-03-24	CSTL	25.39	0.25	98.00	1438
2026-03-25	CSTL	25.24	0.21	0.00	1389
2026-03-26	CSTL	24.68	0.21	0.00	1385
2026-03-27	CSTL	23.56	0.21	20.00	1387
2026-03-30	CSTL	23.53	0.21	20.00	1387
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-02	CSTL	27.97	47.9	-25.8	-1.28
2026-03-03	CSTL	27.60	47.9	-28.4	-1.28
2026-03-04	CSTL	28.20	47.9	-18.3	-1.28
2026-03-05	CSTL	27.90	47.9	-16.5	-1.28
2026-03-06	CSTL	27.11	47.9	-15.5	-1.28
2026-03-09	CSTL	27.01	45.7	-6.3	-1.18
2026-03-10	CSTL	26.58	45.7	-5.6	-1.18
2026-03-11	CSTL	26.13	45.7	-5.5	-1.18
2026-03-12	CSTL	25.32	45.7	-4.8	-1.18
2026-03-13	CSTL	25.56	45.7	-7.0	-1.18
2026-03-17	CSTL	25.88	45.7	-6.5	-1.18
2026-03-18	CSTL	25.66	45.7	-2.0	-1.18
2026-03-19	CSTL	25.70	45.7	-6.6	-1.18
2026-03-20	CSTL	25.05	45.7	-5.1	-1.18
2026-03-23	CSTL	25.73	45.7	-8.1	-1.18
2026-03-24	CSTL	25.37	45.7	-5.7	-1.18
2026-03-25	CSTL	25.25	45.7	-6.2	-1.18
2026-03-26	CSTL	24.70	45.7	-5.2	-1.18
2026-03-27	CSTL	23.55	45.7	-3.9	-1.18
2026-03-30	CSTL	23.56	45.7	-6.5	-1.18
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-02	CSTL	-16.13	-5.11	4.70
2026-03-03	CSTL	-16.13	-5.11	4.70
2026-03-04	CSTL	-16.13	-5.11	4.70
2026-03-05	CSTL	-16.63	-5.11	4.70
2026-03-06	CSTL	-16.63	-5.11	4.70
2026-03-09	CSTL	-17.80	-5.11	4.70
2026-03-10	CSTL	-17.80	-5.11	4.70
2026-03-11	CSTL	-17.80	-5.11	4.82
2026-03-12	CSTL	-17.80	-5.11	4.82
2026-03-13	CSTL	-21.41	-5.11	4.82
2026-03-17	CSTL	-25.26	-5.16	4.82
2026-03-18	CSTL	-25.26	-5.16	4.82
2026-03-19	CSTL	-26.52	-5.16	4.82
2026-03-20	CSTL	-26.52	-5.16	4.82
2026-03-23	CSTL	-26.52	-5.14	4.82
2026-03-24	CSTL	-26.52	-5.14	4.82
2026-03-25	CSTL	-26.52	-5.14	4.94
2026-03-26	CSTL	-26.52	-5.14	4.94
2026-03-27	CSTL	-26.52	-5.14	4.94
2026-03-30	CSTL	-26.52	-5.13	4.94
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.08

Avg. EPS Est. Current Quarter

-0.49

Avg. EPS Est. Next Quarter

-0.31

Insider Transactions

-26.52

Institutional Transactions

-5.13

Beta

1.21

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

26.01

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

70.2

Max Drawdown 5-Year %

-85

Target Price

48.5

P/E

Forward P/E

PEG

P/S

2.03

P/B

1.48

P/Free Cash Flow

24.71

EPS

-0.85

Average EPS Est. Cur. Y

-1.18

EPS Next Y. (Est.)

-0.54

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-7.02

Relative Volume

0.72

Return on Equity vs Sector %

-32.6

Return on Equity vs Industry %

-16.2

EPS 1 7Days Diff

EPS 1 30Days Diff

0.13

EBIT Estimation

-6.5

◆ CSTL Healthcare

$23.55

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

20/20

Pullback

13/25

Volume

9/15

Valuation

15/20

TP/AR

2/10

Options

4/10

RSI

25.2

Range 1M

6.1%

Sup Dist

1.9%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

7/25

Growth

15/30

Estimates

3/20

Inst/Vol

1/15

Options

6/10

EPS Yr

-41.5%

EPS NY

53.7%

52W%

30.4%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +48.6% upside

Quality

6/30

Valuation

14/30

Growth

10/25

Stability

8/10

LT Trend

3/5

Upside

+48.6%

Quality

MoS

10%

Castle Biosciences, Inc.

Sector: Healthcare

Industry: Diagnostics & Research

Employees: 883

Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company offers its products to dermatology and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

CSTL

Latest News

—

Caricamento notizie per CSTL…

stock quote shares CSTL – Castle Biosciences Inc. Stock Price stock today

news today CSTL – Castle Biosciences Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch CSTL – Castle Biosciences Inc. yahoo finance google finance

stock history CSTL – Castle Biosciences Inc. invest stock market

stock prices CSTL premarket after hours

ticker CSTL fair value insiders trading

RVTY – Revvity Inc

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: RVTY

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

XGN – Exagen Inc.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: XGN

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y